(Professor of Psychiatry and Pediatrics)
Dr. Lily Hechtman is a Professor of Psychiatry and Pediatrics at McGill University and Director of Research in the Division of Child Psychiatry. Her research focuses on long-term prospective studies of children with ADHD followed into adolescence and adulthood. She pioneered some of the first controlled long term prospective follow up studies of ADHD as well as multimodal treatment studies. She has also developed Cognitive Behavioral interventions for adults and adolescents with ADHD. At the McGill University Health Center (Montreal Children’s Hospital), she heads a clinical outpatient psychiatry ADHD team specializing in children and adolescents with ADHD and comorbid conditions
Today, effective medication treatments relieve many symptoms of attention deficit hyperactivity disorder (ADHD). Yet medication alone does not resolve the social, academic and emotional challenges that children with ADHD cope with daily and often carry into adulthood.
I have been involved in a joint study with the Université de Montréal to help children with ADHD who fall between the cracks in the transition from elementary school to high school. The program involves parental training as well as mentoring for the children. I have also developed and am piloting a group cognitive behaviour therapy program that focuses on these areas with adolescents and adults with ADHD.
In terms of academic, social and emotional functioning, two large-scale studies in which I participated clearly showed the benefit of combining medication with psychosocial treatment for children with ADHD, as opposed to either treatment alone. However, these benefits do not last without ongoing treatment and follow-up. Another of my current studies aims to determine the optimal follow-up needed to maintain treatment gains. More recently, we developed and tested the efficacy of cognitive-behavioural therapy group interventions for adults with ADHD, and we are currently doing the same for adolescents.
Our ADHD Research Program has been continuously externally funded by the U.S. National Institute of Mental Health (NIMH), the National Institute of Drug Abuse (NIDA) and CIHR since 1988.